Chemotherapy for advanced hepatocellular carcinoma: Systematic chemotherapy or hepatic arterial infusion chemotherapy

Journal of Gastroenterology

Volumn 39, Issue 4, 2004, Pages 404-406

  Yamashita, Tatsuya ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; INTERFERON; MITOXANTRONE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HEPATIC ARTERY; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER TOXICITY; MONOTHERAPY; PRIORITY JOURNAL; TUMOR CLASSIFICATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; NEOPLASM STAGING;

EID: 2542425714     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1330-0     Document Type: Article

References (24)

1. Yang T-S, Chang H-K, Chen J-S, Lin Y-C, Liau C-T, Chag W-C. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. J Gastroenterol 2004;39:362-9.
2. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002;29:119-25.
3. Kuan HY, Smith DE, Ensmiger WD, Knol JA, DeRemer SJ, Yang Z, et al. Regional pharmacokinetics of 5-bromo-2′-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions. Cancer Res 1996;56:4724-7.
4. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular cacinoma. Hepatogastroenterology 1999;46:1122-5.
5. Colombo M, Tommasini MA, Del Ninno E, Rumi MG, De Fazio C, Dioguardi ML. Hepatocellular carcinoma in Italy: report of a clinical trial with intravenous doxorubicin. Liver 1985;5:336-41.
6. Porta C, Moroni M, Nastasi G, Arcangeli G. 5-Fluorouracil and d, l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995;52:487-91.
7. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993;50:22-6.
8. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000;89:750-6.
9. Bobbio-Pallavicini E, Porta C, Moroni M, Bertulezzi G, Civelli L, Pugliese P, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 1997;33:1784-8.
10. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003;23:1891-7.
11. Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol 2002;13: 1771-8.
12. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002;50:305-8.
13. Malik IA, Khan WA, Haq S, Sabin M. A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma. Am J Clin Oncol 1997;20:289-92.
14. Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Principato R, et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002;20:613-25.
15. Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, et al. Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 2002;25:198-203.
16. Yodono H, Sasaki T, Tarusawa K, Midorikawa H, Saito Y, Takekawa SD. Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPE and EAP therapies. Cancer Chemother Pharmacol 1992;31 Suppl:S89-92.
17. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999;6:587-91.
18. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-91.
19. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999;6:587-91.
20. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435-42.
21. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002;62:69-73.
22. Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Fischer H, Cleary K, et al. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 1993;72:2574-82.
23. Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P, et al. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol 1994;17:393-5.
24. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alpha-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21:421-7.